# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price target.
TD Cowen analyst Tara Bancroft upgrades Ocular Therapeutix (NASDAQ:OCUL) from Hold to Buy and raises the price target from $...
Piper Sandler analyst Joseph Catanzaro maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price ...